Stockscreener 앱 받기
14.96
2.71%
0.395
시간 외 거래:
14.82
-0.14
-0.94%
전일 마감가:
$14.56
열려 있는:
$14.55
하루 거래량:
1.50M
Relative Volume:
0.87
시가총액:
$1.20B
수익:
-
순이익/손실:
$-162.45M
주가수익비율:
-8.0232
EPS:
-1.8646
순현금흐름:
$-146.72M
1주 성능:
+0.34%
1개월 성능:
-37.17%
6개월 성능:
+83.11%
1년 성능:
+263.99%
1일 변동 폭
$14.36
$15.05
1주일 범위
$14.28
$16.80
52주 변동 폭
$2.86
$36.26
올레마 Stock (OLMA) Company Profile
명칭
Olema Pharmaceuticals Inc
전화
(415) 651-3316
주소
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
14.96 | 1.17B | 0 | -162.45M | -146.72M | -1.8646 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
올레마 Stock (OLMA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-11 | 개시 | Stifel | Buy |
| 2026-01-07 | 개시 | Piper Sandler | Overweight |
| 2025-10-08 | 개시 | Guggenheim | Buy |
| 2025-08-12 | 재확인 | Citigroup | Buy |
| 2024-04-02 | 개시 | Goldman | Buy |
| 2024-01-30 | 개시 | Citigroup | Buy |
| 2023-07-21 | 개시 | Oppenheimer | Outperform |
| 2023-05-05 | 개시 | CapitalOne | Overweight |
| 2023-02-22 | 개시 | Credit Suisse | Outperform |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-06-09 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-02-28 | 개시 | H.C. Wainwright | Neutral |
| 2021-12-07 | 재개 | Cowen | Outperform |
| 2020-12-14 | 개시 | Canaccord Genuity | Buy |
| 2020-12-14 | 개시 | Cowen | Outperform |
| 2020-12-14 | 개시 | JP Morgan | Overweight |
| 2020-12-14 | 개시 | Jefferies | Buy |
모두보기
올레마 주식(OLMA)의 최신 뉴스
Jefferies Adjusts Price Target for Olema Pharmaceuticals (OLMA) - GuruFocus
Olema Pharmaceuticals (OLMA) Is Down 6.7% After Posting Wider Losses And Filing New Stock Shelf - simplywall.st
Jefferies initiates Olema Pharmaceuticals stock with buy rating By Investing.com - Investing.com Canada
JP Morgan Raises Price Target for Olema Pharmaceuticals (OLMA) | - GuruFocus
Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Olema Pharmaceuticals (OLMA) Drops 33.4% Over Past Month, Reasons Suggest a Potential Turnaround Ahead - Bitget
Olema Pharmaceuticals (OLMA) Loses 33.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Olema Pharmaceuticals (OLMA) Receives Updated Price Target by Go - GuruFocus
The Goldman Sachs Group Issues Pessimistic Forecast for Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price - MarketBeat
HC Wainwright Issues Optimistic Outlook for OLMA Earnings - MarketBeat
OLMA: Guggenheim Lowers Price Target While Maintaining Buy Ratin - GuruFocus
Olema Pharmaceuticals (OLMA) Receives Increased Price Target fro - GuruFocus
Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting - Bitget
Lab study: Olema drug duo hits cancer growth and spread genes - Stock Titan
Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS) and Olema Pharmaceuticals (OLMA) - The Globe and Mail
Citigroup Forecasts Strong Price Appreciation for Olema Pharmaceuticals (NASDAQ:OLMA) Stock - MarketBeat
Olema Pharmaceuticals (NASDAQ:OLMA) Trading Down 5.2% Following Analyst Downgrade - MarketBeat
OLMA: Guggenheim Lowers Price Target While Maintaining Buy Rating | OLMA Stock News - GuruFocus
Olema Pharmaceuticals (NASDAQ:OLMA) Price Target Cut to $38.00 by Analysts at Guggenheim - MarketBeat
Guggenheim lowers Olema Pharmaceuticals price target on trial timing By Investing.com - Investing.com Canada
Breakout Zone: Should I invest in Olema Pharmaceuticals Inc before earningsWeekly Stock Recap & AI Powered Market Trend Analysis - baoquankhu1.vn
Decoding Olema Pharmaceuticals inc (OLMA): A Strategic SWOT Insi - GuruFocus
Olema Pharmaceuticals (OLMA) Stock Rises 9% After Q4 Earnings Beat - MEXC
Short Covering: Does Olema Pharmaceuticals Inc have pricing powerVolume Spike & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch - The Motley Fool
Biotech shares surge almost 300% as $68.7 million investment backs breast cancer treatment aiming for 2027 debut - Bitget
Olema Oncology Reports 2025 Financial Results and Advances Palazestrant in Phase 3 Breast Cancer Trials - Minichart
Shane W. Kovacs sells 241,999 OLMA shares (NASDAQ: OLMA) for $3.25M - Stock Titan
Olema Pharmaceuticals (OLMA) Stock Jumps 9% Following Fourth Quarter Earnings Surprise - MEXC
[144] Olema Pharmaceuticals, Inc. SEC Filing - Stock Titan
Olema Pharmaceuticals 2025 Annual Report: Pipeline Progress, Risk Factors, and Breast Cancer Therapy Insights - Minichart
Olema Pharmaceuticals (NASDAQ:OLMA) Trading Up 8.5% on Earnings Beat - MarketBeat
Olema Pharmaceuticals delivers Q4 and full-year 2025 financial results and updates on milestones - Traders Union
Olema Pharmaceuticals (OLMA) Reports Q4 Earnings Beat - GuruFocus
Olema Oncology (OLMA) Advances Key Cancer Therapies in 2025 - GuruFocus
Olema Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Olema Pharmaceuticals Inc (OLMA) announced that patient recruitment for the Phase 1 clinical study of its candidate drug OP-3136 is underway. - Bitget
854,000 Shares in Olema Pharmaceuticals, Inc. $OLMA Acquired by Kingdon Capital Management L.L.C. - MarketBeat
Olema Oncology reports Q4 EPS (50c), consensus (53c) - TipRanks
Olema Pharmaceuticals (NASDAQ:OLMA) Posts Earnings Results - MarketBeat
Olema 10-K: $0 Revenue, $(1.87) EPS and $(162.5)M Net Loss - TradingView
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results - The Manila Times
Oncology drug developer Olema Pharmaceuticals' Q4 net loss widens on higher R&D costs - TradingView
Olema Pharmaceuticals (NASDAQ: OLMA) outlines late-stage breast cancer drug pipeline - Stock Titan
HighVista Strategies LLC Acquires 158,749 Shares of Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Oncology (NASDAQ: OLMA) boosts cash as 2025 loss widens on R&D - Stock Titan
BRIEF-Olema Pharmaceuticals Q4 Net Income USD -46.061 Million - TradingView
Breast cancer drug developer Olema amasses $505M cash as 2025 loss widens - Stock Titan
Guggenheim Initiates Coverage of Olema Pharmaceuticals (OLMA) with Buy Recommendation - MSN
OLMA Should I Buy - Intellectia AI
Pier Capital LLC Has $5.13 Million Holdings in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
올레마 (OLMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):